SENTI-202

环球视野，深度视角 各位亲爱的股东，大家早上好中午好晚上好！ 翻了翻，上次聊Senti还是2024年... PART.01 “背刺” 2026年7月15日，创新药企Senti Biosciences的投资人们被“背刺”了。 交易盘前，公司官网挂出一份公告： “（Senti）宣布一项战略交易，以释放其基因电路赋能管线（包括 SENTI-202）的价值，并借助其 Regulator Dial 技术平台，更加专注于下一代可控基因药物” 这要不知道的还以为公司拿下了大单了，就要起飞了... 然而，这其实是PR的魅力时刻。 这份公告，核心内容其实只有一个：剥离公司核心资产。 公司最大投资者 Celadon 关联方控制的新成立私营生物技术公司（“NewCo”）将收购公司与其基因电路赋能管线相关的资产，包括 SENTI-202 的权利。 那有人要说了，这怎么能算背刺呢？这应该算BD出去了呀，该高兴才是啊。 Emmm，从投资人的反应来看，这纯纯的就是背刺。 因为消息发布当日，Senti股价暴跌近40%。 Why？ PART.02 “取卵” SENTI-202是Senti的核心资产，该款药物为“现货型”CAR-NK细胞疗法产品，适应症为复发难治血液瘤包括AML、MDS等。 第一，SENTI-202通过双价CD33和/或FLT3靶向潜在的深度和持久反应; 第二，通过在健康造血干细胞（HSCs）上特有表达的内皮素（EMCN）保护抗原提供潜在的改善安全性和增加治疗窗口; 第三，校准释放IL-15：潜在增加细胞扩增、持续性和杀伤肿瘤的能力。 SENTI-202引入“基因电路”概念，通过独有的逻辑门技术，旨在克服AML的疾病异质性。 目前，已经获得FDA 再生医学先进疗法（RMAT）认定，针对 AML 及其他血液癌症适应症。 不仅如此，SENTI-202几乎可以说是Senti的唯一资产。 Pipeline里面的保密项目从头到尾都没让大家看到过，甚至都让人怀疑是否存在过。 你把唯一的核心资产卖了，后面干啥呢？ 公司表示交易完成后，Senti计划寻求额外融资，使其团队能够专注于推进基于其专有 Regulator Dial平台构建的早期项目，包括针对 Rett 综合征的可控基因疗法，以及针对实体瘤的可控、装甲型肿瘤浸润淋巴细胞（“TILs”），旨在提高疗效和安全性。 合着还要融资啊，你这是卖了几个钱？ PART.03 “贱” NewCo 计划继续开发 SENTI-20以及其他用于实体瘤的逻辑门控疗法和基因电路赋能项目，如体内 CAR。 CVR （或有价值）里程碑结构如下： SENTI-202 的生物制品许可申请（BLA）提交并获受理后支付 1000 万美元； SENTI-202 的 BLA 获得 FDA 批准后支付 2000 万美元； SENTI-202 累计净销售额达到 2 亿美元后支付 3000 万美元。 合着最多也就能拿6000万美元，拿到BLA后才能拿到2000万美元啊... 那特么Senti累计亏损的3.62亿美元算什么？算投资人的爱吗？ 是谁信誓旦旦的说“未被满足的巨大市场，数十亿美元庞大市场机遇”？ 哦，对，机遇...潜力... 贱不贱啊...唉，这饼，就吃了吧。 PART.04 “干涸” “这项交易将使两家公司能够集中资源，加速向多种疾病领域的患者提供强效的新型基因药物，同时让 Senti股东有可能从两个实体的成功中获益，”公司首席执行官 Timothy Lu博士表示。 然而，NewCo一共就能给Senti 6000万美元，而Senti则要背着3个多亿的亏损，你告诉我股东能从两家都获益.... 瞄了眼，擦，Senti的股价已经下滑了99.42%。 如果在上市时您投资了10万美元，如今还能剩下580美元。 还得是美国，真猛！ 所以朋友们，创新药在美国确实是高收益，然而另一面就是绝对的高风险。 PS：写这个PR的是哪位大神？以后我们的推文标题能帮忙提供点建议不？ 好了，今天的瓜就先吃到这里，明天的瓜我们明天再吃，散会！ tags：#Senti     #创新药     #CGT END 各位股东看了么？赞了么？转发了么？别忘了点赞。谢谢！ 所有内容均不作为投资建议，信息均来自公开资料，星球更新更快。 扫码加入星球！ 循因缉药Elite PS:风里雨里，老编等你~ 近期原创： 都怪中国和中东！纳米孔测序龙头2026年中报不及预期 蛋白组学上市公司董事会控制权攻防白热化！ 肠癌早筛临床结果达到所有终点，结果怒亏3000万美元 追着打！23andMe判赔4675万美元 相关资料： 注1：https://investors.sentibio.com/news-releases/news-release-details/senti-biosciences-holdings-inc-announces-strategic-transaction

South San Francisco-based Senti Biosciences Holdings (Nasdaq: SNTI) is divesting its gene-circuit-enabled pipeline — including its most advanced clinical asset — to a newly formed private company, restructuring itself around an earlier-stage technology platform it believes addresses a fundamental limitation of current genetic medicines. The strategic transaction transfers the company’s Gene-Circuit-enabled pipeline, including SENTI-202 (an allogeneic NK cell therapy for relapsed/refractory acute myeloid leukemia), to a newly formed private entity — referred to as NewCo — controlled by affiliates of Celadon, Senti’s largest investor. In exchange, Senti’s stockholders will receive a contingent value right structured around three milestone payments totaling up to USD 60 million over seven years: USD 10 million upon BLA filing and acceptance, USD 20 million upon FDA approval, and USD 30 million upon reaching USD 200 million in cumulative net sales of SENTI-202. The transaction requires approval from Senti stockholders and satisfaction of other customary closing conditions. Definitive transaction documents will be filed with the SEC. SENTI-202 carries meaningful clinical momentum — it holds FDA Regenerative Medicine Advanced Therapy designation and generated durable MRD-negative responses in a Phase I trial — but advancing it through late-stage development and potential commercialization demands capital and operational focus that a single company pursuing two distinct technology platforms would struggle to sustain simultaneously. The company also said it has identified a donor characteristic—referred to as “Donor X”—that was associated with higher response rates in the Phase I study and plans to incorporate this donor selection strategy into future SENTI-202 manufacturing and clinical development. By separating the Gene-Circuit-enabled pipeline into a privately held company, SNTI allows each organization to pursue distinct development strategies while giving existing stockholders continued economic exposure to SENTI-202 through the contingent value right. Senti has indicated it will seek additional financing following close to fund its retained programs — suggesting the current balance sheet is insufficient to support both platforms independently. The divestiture removes SENTI-202 and the broader Gene-Circuit franchise from Senti’s consolidated pipeline. NewCo will also advance other Logic Gate-enabled programs for solid tumors and in vivo CAR approaches. What remains at Senti centers on its proprietary Regulator Dial technology platform, which the company describes as enabling dynamic control of genetic medicines after administration. Two early-stage programs are retained: a controllable gene therapy targeting Rett syndrome and controllable, armored tumor-infiltrating lymphocytes for solid tumors. Both are preclinical or early-stage relative to SENTI-202. The restructuring repositions SNTI from a company with a clinical-stage cell therapy asset to one focused entirely on controllable genetic medicines at an earlier development stage. The Regulator Dial platform, which integrates synthetic biology and artificial intelligence to engineer post-administration control into genetic medicines, becomes the company’s defining asset and commercial proposition. The restructuring reduces SNTI’s near-term clinical development obligations but also removes its most advanced clinical asset and clearest near-term value inflection point. The CVR provides contingent upside but no guaranteed near-term cash. The competitive landscape for controllable gene therapies remains sparse at the clinical level, though several companies are pursuing synthetic biology-based approaches to cell and gene therapy precision. SNTI’s differentiation will depend on whether the Regulator Dial platform can generate compelling preclinical and early clinical data in Rett syndrome and TIL therapy, two areas with distinct competitive dynamics. Stockholder approval is the immediate gating event. Beyond that, the key indicators will be whether SNTI secures sufficient post-close financing to meaningfully advance its Rett syndrome and TIL programs, and whether NewCo maintains SENTI-202’s clinical momentum toward a potential BLA filing — the first milestone that would trigger a USD 10 million CVR payment to SNTI stockholders. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.